Abstract

Mamta M. Andhale*, Prashant V. Ajmire, Pramod V. Burakle

ABSTRACT

Objective: The primary goal for individuals with type 2 diabetes is to achieve optimal glucose control to prevent long-term complications. This review aims to explore the synergistic effects of combining lobeglitazone and glimepiride for improved glycemic management. Methods: A comprehensive analysis of existing literature was conducted, focusing on the pharmacological interactions between various oral glucose-lowering agents. Specific attention was given to the combination therapy of lobeglitazone, a thiazolidinedione (TZD), and glimepiride, a sulfonylurea, to evaluate their potential in enhancing glycemic control. Results: Monotherapy often fails to maintain adequate glycemic control over time, necessitating the use of combination therapies. Several drug classes, including alpha-glucosidase inhibitors, metformin, sulfonylureas, non-sulfonylurea secretagogues (meglitinide derivatives), and TZDs, demonstrate synergistic effects when used together. The combination of lobeglitazone and glimepiride has shown promising results, significantly reducing blood glucose levels and improving insulin sensitivity. Conclusion: Combining lobeglitazone and glimepiride may offer a superior therapeutic approach to managing type 2 diabetes by addressing both insulin resistance and insulin secretion deficits. However, further clinical trials are essential to fully evaluate the long-term benefits, safety profile, and potential drawbacks of this combination therapy.